J B Chemicals & Pharmaceuticals Ltd
J B Chemicals & Pharmaceuticals Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
The short version
India business expected to grow 200 to 300 basis points better than the market in Q4 FY '26, driven by volume growth especially in chronic therapies. Q4 FY'26 guidance indicates India business to grow 200 to 300 basis points above the market and international business to grow high single digit, continuing Q3 momentum.
From J B Chemicals & Pharmaceuticals Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- India business expected to grow 200 to 300 basis points better than the market in Q4 FY '26, driven by volume growth especially in chronic therapies.
- Domestic business growth guidance maintained at around 11-12% year-to-date, continuing to outperform the Indian pharma market.
- International business to grow at high single-digit for the full year FY '26, with strong order book momentum in Q4 supporting sustained growth.
- Export formulation business and subsidiaries in South Africa and Russia showing robust performance with double-digit growth expected in Q4.
- CDMO segment expected to grow 10-12% in FY '27, with quarterly run rates around INR115-120 crore.
2 more points from J B Chemicals & Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what J B Chemicals & Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what J B Chemicals & Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- For Q4 FY '26, J.B. Pharma has a good order book expected to drive performance similar to Q3.
- International business, including subsidiaries in South Africa and Russia, benefits from strong order book momentum.
- Export branded business also performing well, contributing to growth.
- Guidance expects quarter 4 international business to show double-digit growth.
- Overall for the year, international business is projected to grow at a high single-digit rate.
2 more points from J B Chemicals & Pharmaceuticals Ltd's call on order book
Create a free account to keep reading this call
J B Chemicals & Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹904 Cr, net profit ₹101 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What J B Chemicals & Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules Ltd (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn Ltd (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharmaceuticals Ltd (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
J B Chemicals & Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were J B Chemicals & Pharmaceuticals Ltd Q3 FY26 results?
India business expected to grow 200 to 300 basis points better than the market in Q4 FY '26, driven by volume growth especially in chronic therapies. Q4 FY'26 guidance indicates India business to grow 200 to 300 basis points above the market and international business to grow high single digit, continuing Q3 momentum.
What is J B Chemicals & Pharmaceuticals Ltd share price analysis?
J B Chemicals & Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 53.8 with a market cap of ₹38,677 Cr. Investors should review the full earnings analysis for detailed insights.
Keep J B Chemicals & Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.